Ropivacaine

• (S )-1 -propyl-2 ', 6'- dimethyl-2- piperidylcarboxyanilid
• (-) -1 -propyl-2 ', 6'- dimethyl-2- piperidylcarboxyanilid

• 84057-95-4 ( ropivacaine )
• 98717-15-8 ( · ropivacaine hydrochloride)
• 132112-35-7 ( ropivacaine hydrochloride · · monohydrate)

N01BB09

Local anesthetics

8.1

Hydrochloride monohydrate ·

Risk

Template: Infobox chemical / molecular formula search available

Ropivacaine (trade name: Naropin ®, Ropivacin ®) is a local anesthetic of the amide type. It is derived from bupivacaine, and has a relatively slow onset of action and a long duration of activity ( up to 12 hours). It was founded in 1985 by Apothekernes Laboratory - Oslo, Norway - patented and marketed throughout Europe by AstraZeneca.

Application

It is used in anesthesia for conduction anesthesia and epidural anesthesia procedures such as epidurals.

Special

After Ropivacaingabe the motor blockade in the operational area should be less pronounced with the same pain relief. This property makes it a much substance used in obstetrics and for pain therapy after orthopedic surgery, as this pain-free mobilization of the patient is simplified. In addition, it should be less heart - and neurotoxic than comparable other local anesthetics. With regard to the maximum dose is given in the SmPC of Naropin that for epidural anesthesia in surgical procedures, single doses up to 250 mg ropivacaine (equivalent to approximately 33 ml ropivacaine 0.75 %) was applied and well tolerated. A limited number of patients received for brachial plexus blockade a single dose of 300 mg (equivalent to approximately 40 ml ropivacaine 0.75 %), which were also well tolerated.